Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Patients with metastatic colorectal cancer will be treated with chemotherapy according to investigators choice. In addition to chemotherapy treatment, treatment with bevacizumab will be given concomitantly. This treatment will continue during 18 weeks. Meanwhile, the patients KRAS status will be tested. After having fulfilled these 18 weeks of induction treatment, patients who has responded (complete response/partial response versus stable disease) will be randomized to maintenance treatment. Patients with KRAS WT will be randomized to either bevacizumab alone, or to bevacizumab and erlotinib. Patient with KRAS mutation will be randomized to either bevacizumab, or metronomic capecitabine. Translational research is performed, with purpose to find predictive factors in blood and tumor tissue.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B
B: Arm Label: bevacizumab and erlotinib (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, erlotinib | Arm Label: bevacizumab (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: bevacizumab (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: low dose capecitabine (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: low dose capecitabine | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): bevacizumab and erlotinib (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS mutated) | Intervention Type: DRUG; Name: low dose capecitabine; Assigned to Arm(s): low dose capecitabine (KRAS mutated)
C: Arm Label: Arm B: FOLFOXIRI & bevacizumab (inclusion completed); Type: EXPERIMENTAL; Interventions: Drug: FOLFOXIRI with bevacizumab | Arm Label: Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed); Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFOX/ FOLFIRI with bevacizumab | Arm Label: Arm D: FOLFOX/FOLFIRI & panitumumab; Type: EXPERIMENTAL; Interventions: Drug: FOLFOX/ FOLFIRI with panitumumab | Arm Label: Arm C: FOLFOX/ FOLFIRI & bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFOX/ FOLFIRI with bevacizumab | Intervention Type: DRUG; Name: FOLFOX/ FOLFIRI with bevacizumab; Assigned to Arm(s): Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed), Arm C: FOLFOX/ FOLFIRI & bevacizumab | Intervention Type: DRUG; Name: FOLFOXIRI with bevacizumab; Assigned to Arm(s): Arm B: FOLFOXIRI & bevacizumab (inclusion completed) | Intervention Type: DRUG; Name: FOLFOX/ FOLFIRI with panitumumab; Assigned to Arm(s): Arm D: FOLFOX/FOLFIRI & panitumumab
D: Arm Label: bevacizumab alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: Bevacizumab + erlotinib; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab alone | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): Bevacizumab + erlotinib

Answer: B